Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans

Nephrology Dialysis Transplantation

Volumn 26, Issue 11, 2011, Pages 3805-3810

  Freedman, Barry I ^a   Langefeld, Carl D ^a   Murea, Mariana ^a   Ma, Lijun ^a   Otvos, James D ^b   Turner, Jolyn ^a   Antinozzi, Peter A ^a   Divers, Jasmin ^a   Hicks, Pamela J ^a   Bowden, Donald W ^a   Rocco, Michael V ^a   Parks, John S ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b LIPOSCIENCE INC   (United States)

Author keywords

APOL1; arteriolar nephrosclerosis; FSGS; HDL cholesterol; kidney

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AFRICAN AMERICAN; APOLIPOPROTEIN L1 GENE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; GLOMERULUS FILTRATION RATE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; KIDNEY DISEASE; LIPOPROTEIN BLOOD LEVEL; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PEDIGREE ANALYSIS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AFRICAN AMERICANS; APOLIPOPROTEINS; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS;

EID: 80155172526     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr542     Document Type: Article

References (37)

1. Appel LJ, Wright JT Jr, Greene T et al. Long-term effects of reninangiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Int Med 2008; 168: 832-839
2. Appel LJ, Wright JT Jr, Greene T et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010; 363: 918-929
3. Kopp JB, Smith MW, Nelson GW et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008; 40: 1175-1184
4. Kao WH, Klag MJ, Meoni LA et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008; 40: 1185-1192
5. Freedman BI, Hicks PJ, Bostrom MA et al. Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int 2009; 75: 736-745
6. Genovese G, Friedman DJ, Ross MD et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329: 841-845
7. Tzur S, Rosset S, Shemer R et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 2010; 128: 345-350
8. Freedman BI, Kopp JB, Langefeld CD et al. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J Am Soc Nephrol 2010; 21: 1422-1426
9. Astor BC, Lipkowitz MS, Kao WH et al. MYH9 variations are associated with chronic kidney disease progression in the African American Study of Hypertension and Kidney Disease (AASK). J Am Soc Nephrol 2010; 21: 81A abstract
10. Lipkowitz MS, Iyengar SK, Molineros J et al. Association analysis of the non-muscle myosin heavy chain 9 gene (MYH9) in hypertensive nephropathy: African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol 2009; 20, 56A, abstract
11. Freedman BI, Hicks PJ, Bostrom MA et al. Non-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRD. Nephrol Dial Transplant 2009; 11: 3366-3371
12. Freedman BI, Kopp JB, Winkler CA et al. Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with albuminuria in hypertensive African Americans: The HyperGEN study. Am J Nephrol 2009; 29: 626-632
13. Bostrom MA, Freedman BI. The spectrum of MYH9-associated nephropathy. Clin J Am Soc Nephrol 2010; 5: 1107-1113
14. Reeves-Daniel AM, Iskandar SS, Bowden DW et al. Is collapsing C1q nephropathy another MYH9-associated kidney disease? A case report. Am J Kidney Dis 2010; 55: E21-e24
15. Nelson GW, Freedman BI, Bowden DW et al. Dense mapping of MYH9 localizes the strongest kidney disease associations to the region of introns 13 to 15. Hum Mol Genet 2010; 19: 1805-1815
16. Fogo A, Breyer JA, Smith MC et al. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: A report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. Kidney Int 1997; 51: 244-252
17. Marcantoni C, Ma LJ, Federspiel C, Fogo AB Hypertensive nephrosclerosis in African Americans versus Caucasians. Kidney Int 2002; 62: 172-180
18. Freedman BI, Iskander SS, Buckalew VM Jr et al. Renal biopsy findings in presumed hypertensive nephrosclerosis. Am J Nephrol 1994; 14: 90-94
19. Soedamah-Muthu SS, Chang YF, Otvos J et al. Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type 1 diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2003; 46: 674-682
20. Rosenson RS, Brewer HB Jr, Chapman MJ et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011; 57: 392-410
21. Keene KL, Mychaleckyj JC, Leak TS et al. Exploration of the utility of ancestry informative markers for genetic association studies of African Americans with type 2 diabetes and end stage renal disease. Hum Genet 2008; 124: 147-154
22. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470
23. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006; 26: 847-870
24. Otvos JD, Shalaurova I, Freedman DS, Rosenson RS. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis 2002; 160: 41-48
25. Miljkovic-Gacic I, Bunker CH, Ferrell RE et al. Lipoprotein subclass and particle size differences in Afro-Caribbeans, African Americans, and white Americans: Associations with hepatic lipase gene variation. Metabolism 2006; 55: 96-102
26. Freedman BI, Iskandar SS, Appel RG. The link between hypertension and nephrosclerosis. Am J Kidney Dis 1995; 25: 207-221
27. Murea M, Freedman BI. Essential hypertension and risk of nephropathy: A reappraisal. Curr Opin Nephrol Hypertens 2010; 19: 235-241
28. Kuller LH, Grandits G, Cohen JD et al. Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome. Atherosclerosis 2007; 195: 122-128
29. Duchateau PN, Pullinger CR, Orellana RE et al. Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L. J Biol Chem 1997; 272: 25576-25582
30. Timmins JM, Lee JY, Boudyguina E et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 2005; 115: 1333-1342
31. Axler O, Ahnstrom J, Dahlback B. An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma. J Lipid Res 2007; 48: 1772-1780
32. Mulya A, Seo J, Brown AL et al. Apolipoprotein M expression increases the size of nascent pre beta HDL formed by ATP binding cassette transporter A1. J Lipid Res 2010; 51: 514-524
33. Rye KA, Clay MA, Barter PJ Remodelling of high density lipoproteins by plasma factors. Atherosclerosis 1999; 145: 227-238
34. Settasatian N, Duong M, Curtiss LK et al. The mechanism of the remodeling of high density lipoproteins by phospholipid transfer protein. J Biol Chem 2001; 276: 26898-26905
35. Reeves-Daniel AM, Depalma JA, Bleyer AJ et al. The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant 2011; 11: 1025-1030
36. Reeves-Daniel AM, Divers J, Langefeld CD et al. Response to mechanism of action of APOL1 in renal allograft survival (and native CKD) remains unclear. Am J Transplant 2011doi: 10.1111/j.1600-6143. 2011.03672.x
37. Murea M, Freedman BI, Parks JS et al. Lipotoxicity in diabetic nephropathy: The potential role of fatty acid oxidation. Clin J Am Soc Nephrol 2010; 5: 2373-2379